Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Rein Therapeutics, Inc. incurred senior notes of $2,875,000 with three institutional investors at 20% original issue discount maturing the earlier of (i) the date of the closing of the next issuance and sale of securities of the Company, in a single transaction or series of related transactions.
- Instrument
- senior notes
- Principal
- $2,875,000
- Counterparty
- three institutional investors
- Rate
- 20% original issue discount
- Maturity
- the earlier of (i) the date of the closing of the next issuance and sale of securities of the Company, in a single transaction or series of related transactions
- Event
- incurrence
Exact text from the filing
On February 24 and 27, 2026, Rein Therapeutics, Inc. (the “Company”) entered into separate securities purchase agreements (each a “Purchase Agreement”) with three institutional investors pursuant to which the Company issued and sold to the investors, in a private placement, unsecured promissory notes in the aggregate original principal amount of $2,875,000 (each a “Note”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Rein Therapeutics, Inc. entered into Purchase Agreement with three institutional investors valued at $2,875,000.
- Action
- entry
- Agreement
- notes offering
- Counterparty
- three institutional investors
- Value
- $2,875,000
Exact text from the filing
On February 24 and 27, 2026, Rein Therapeutics, Inc. (the “Company”) entered into separate securities purchase agreements (each a “Purchase Agreement”) with three institutional investors pursuant to which the Company issued and sold to the investors, in a private placement, unsecured promissory notes in the aggregate original principal amount of $2,875,000 (each a “Note”).
View on SEC.gov